StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb (BMY) Falls Following Astra's Mystic Data; Merck (MRK) Gains
July 27, 2017 6:49 AM
Bristol-Myers Squibb (NYSE: BMY) declined after AstraZeneca (NYSE: AZN) said its combination of Imfinzi and tremelimumab did ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Trader Talk
Next Articles
Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
July 31, 2017 9:41 AM
Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners
July 28, 2017 10:31 AM
Bristol-Myers Squibb's (BMY) Call Didn't Alleviate Concerns - BMO
July 27, 2017 12:38 PM
AstraZeneca (AZN) Posts Q2 EPS of $0.38; Reiterates Outlook
July 27, 2017 6:56 AM
AstraZeneca (AZN) Shares Plunge After MYSTIC Trial Did Not Meet Primary Endpoint
July 27, 2017 5:49 AM
